Niagen Bioscience (NAGE) Q3 2026 earnings review
Niagen Bioscience sales drop 20% and online growth turns negative
Niagen Bioscience, the maker of Tru Niagen healthy-aging supplements, swung to a loss as both online and ingredient sales shrank. Sales from continuing businesses fell 18%, while high marketing and overhead costs pushed the company to a $1.6 million operating loss. Chief executive Rob Fried called 2026 an investment year for new skincare, injectable, and drug lines, but management cut its full-year online growth plan to 5% and said weaker retail partner orders will wipe out those gains.
| Sales from continuing businesses | $27.2M -18.1% from a year ago |
|---|---|
| Online consumer sales | $18.2M -4.2% from a year ago |
| Operating loss | -$1.6M $4.2M profit a year ago |
| Full-year online sales outlook | Cut to ~5% prior 10%–15% growth plan |
⚖️ Verdict: 🔴 Bearish
The story got worse because the slowdown spread from wholesale ingredients into the core online consumer business. Last quarter, management dropped its total company growth plan but pointed to 10% to 15% online growth as the anchor; now e-commerce has turned negative and by our math total Tru Niagen sales will not grow at all this year. One bright spot: collecting past-due Asian receivables brought in $2.6 million of operating cash flow and lifted cash to $69.5 million.
The question now is whether heavy marketing spend and new retail shelves at Walmart, GNC, and Sam's Club can revive consumer growth in 2027, or if cheaper rival supplements have permanently capped demand. If the new campaigns work, fourth-quarter online sales will beat the 1.5% decline implied by the outlook; if rivals keep winning, consumer revenue will continue to contract. Fourth-quarter e-commerce revenue and marketing expenses will tell.
🐂 Bull Case
Direct Website Sales Grow as Retail Expands
Niagen Bioscience sells Tru Niagen, its main healthy-aging dietary supplement, through its own website, third-party online marketplaces like Amazon, and retail stores. While total online revenue fell this quarter, direct sales on the company's own website grew 13% from a year ago. For the full year, management expects direct website revenue to rise 15% to 20%, showing that loyal customers still buy directly from the brand.
To reduce its reliance on a single online marketplace, the supplement maker also expanded its store footprint. In the third quarter, it started selling on Walmart.com and "launched at nearly 300 GNC and Sam’s Club locations across 44 states combined". By contrast, the release gave no update on cross-border sales into China, a growth driver earlier this year that awaits the quarterly filing.
What to watch: fourth-quarter direct website sales against the 15% to 20% full-year target. Hitting that range while third-party online marketplaces struggle would prove the brand campaign is bringing shoppers straight to the company's own site.
Receivables Collection Kept Cash Flow Positive
Despite swinging to a net loss of $1.2 million in the third quarter, the Los Angeles group generated $2.6 million in cash from operations. Working capital provided a $1.9 million cash inflow because trade receivables fell to $6.8 million from $8.6 million in June after an Asian retail partner released previously withheld payments. Cash ended the quarter at $69.5 million with no debt.
After spending $5.1 million on share buybacks in the first half of 2026 and setting up a $50 million stock-sale programme in June, management neither bought back shares nor issued new stock under that facility in the third quarter. Holding onto cash preserves a cushion against a potential $10.4 million legal fee award in the Elysium dispute, which went unmentioned in the release.
What to watch: operating cash flow in the fourth quarter once the one-time boost from collecting past-due Asian receivables fades. Continuing to generate cash without working-capital help would show the core supplement business can self-fund next year's research plans.
🐻 Bear Case
Online Sales Drop Forced an Outlook Cut
Last quarter, after dropping its full-year total revenue target, Niagen Bioscience anchored its growth story on online sales of Tru Niagen, forecasting 10% to 15% growth for 2026. In the third quarter, e-commerce revenue instead shrank 4.2% from a year ago to $18.2 million. Because direct website sales grew 13%, the drop came from third-party online marketplaces, where the company has battled rival supplements.
- Online sales: $18.2 million, down 4.2% from a year ago after growing 13.3% in the second quarter
- Watson's and other business-to-business consumer sales: $5.2 million, down 25.7% from a year ago
- Implied fourth-quarter online sales: $19.9 million, down 1.5% from a year ago by our math
- Implied full-year total Tru Niagen sales: $97.7 million, unchanged from 2025 by our math
Management cut its full-year e-commerce growth forecast in half, to about 5%, and warned that weaker retail partner orders will "offset the growth of the e-commerce business". By our math, that means fourth-quarter online sales will decline about 1.5% and full-year Tru Niagen revenue will not grow at all.
What to watch: fourth-quarter e-commerce revenue against the $19.9 million implied by the full-year outlook. A second straight quarterly decline would show that competition on third-party marketplaces is eroding the main consumer franchise.
Rival Supplements Cut Ingredient Sales in Half
Alongside its own consumer bottles, the bioscience group sells raw nicotinamide riboside (NR), its patented cellular-energy ingredient, to other supplement brands. Third-quarter Niagen ingredient revenue fell 44.9% from a year ago to $3.8 million, with food-grade ingredient sales dropping 46.9% to $3.4 million. The company blamed "decreased volume from key ingredient partners due to competitive market dynamics" as cheaper alternatives like NMN take shelf space.
To fight back, the company added new partners in the third quarter and plans to introduce "a lower-cost NR salt form, patented by Niagen Bioscience, which is expected to reduce cost of goods sold and strengthen the ingredient business". However, selling a cheaper version risks lowering revenue per kilogram even if volumes recover, and the release gave no update on Thorne's legal challenge to the company's core '506 patent.
What to watch: quarterly food-grade ingredient revenue and gross margin in the fourth quarter. A further drop below $3.4 million would strain the company's $20.5 million purchase commitment with its supplier through June 2027.
Heavy Marketing Pushed the Quarter Into Loss
The company stated that its 62.9% gross margin "reflects the strength of its operational foundation", while chief executive Rob Fried called 2026 an investment year that "provides a strong springboard for meaningful growth in 2027 and beyond". In reality, gross margin fell 1.6 percentage points from 64.5% a year ago, and operating profit swung from a $4.2 million gain to a $1.6 million loss.
Operating margin dropped 18.3 percentage points, to negative 5.8%, because spending stayed high while sales shrank 20%. Advertising and marketing costs rose 6.2 percentage points of revenue to 32.0% as the group launched its Kelly Slater celebrity campaign, while general and administrative overhead jumped 9.1 percentage points to 30.1%. Spending a third of revenue on marketing failed to keep online sales from shrinking.
What to watch: sales and marketing expense as a share of revenue in the fourth quarter. Staying above 30% while total consumer sales remain flat would mean customer acquisition costs have permanently risen.
New Ventures Expand While Injectable Sales Shrink
Supporters view Niagen Bioscience's expansion into clinic infusions, telehealth injections, skincare, and prescription drugs as multiple shots on goal for 2027. This quarter the company launched its liquid Niagen At-Home Injection Kit, introduced Niagen NanoCloud, a topical skin product, hired advisers at Red Sky Partners for its NB4168 rare-disease drug candidate, and signed a planning deal with Mass General Brigham for "what is envisioned to be the largest and most comprehensive clinical trial of Niagen to date".
However, the one new vertical that already reports a revenue line is shrinking. Sales of pharmaceutical-grade Niagen, which supplies clinics and the telehealth platform launched in May, fell 20% from a year ago to $0.4 million and remained stuck at second-quarter levels. Management omitted the clinic count for a second straight quarter and pushed meaningful revenue from injectables and skincare out to 2027.
What to watch: fourth-quarter pharmaceutical-grade Niagen sales and whether management lowers clinic pricing as previously discussed. Another $0.4 million quarter would show that at-home injection kits are not yet gaining patient traction.
💲 Other KPIs
Sales from businesses owned a year ago — stripping out the analytical reference standards unit sold in February — fell 18.1% from a year ago, compared with a 20.0% drop in total reported revenue. That marks a sharp downturn from 3.7% growth in the first quarter and a 1.7% dip in the second quarter.
Profit before interest, taxes, depreciation, and stock-based pay — a cash-proxy profit measure the company calls Adjusted EBITDA — fell 92.8% from $6.4 million a year ago. It has declined for four straight quarters, from $4.1 million in the fourth quarter of 2025 to $3.8 million in the first quarter and $3.0 million in the second.
Stockpiled goods and raw ingredients rose 9.2% from $18.8 million a year ago even as quarterly sales fell by a fifth. Compared with $20.6 million in June and $20.4 million at the end of 2025, inventory levels have barely budged despite weaker ingredient demand.
🔮 Guidance
Cut. The company lowered its full-year online sales growth plan from a 10%–15% range down to about 5%. By our math, after generating $57.9 million in the first nine months, that leaves about $19.9 million for the fourth quarter, a 1.5% decline from a year ago. Management also expects drops in the rest of the consumer business to wipe out all online dollar gains this year.
New. Management issued a standalone full-year growth target of 15% to 20% for direct sales on its own website, compared with 13% growth in the third quarter and 23% in the second quarter. Breaking out website sales highlights that the cut to total online growth comes from third-party marketplaces rather than the company's own storefront.
Unchanged. The plan still calls for full-year ingredient revenue to finish below last year's $27.9 million because key partners are ordering less amid stiffer competition. Through the first nine months, Niagen ingredient sales totaled $17.4 million, down 22% from $22.3 million in the same period of 2025, making a full-year decline certain.
Unchanged. The supplement group still plans to spend more across marketing, research, and administration this year to fund its new product lines, while aiming to keep full-year operating cash flow positive. Over the first nine months, total operating expenses rose 13.0% from a year ago to $55.7 million.
❓ Key Questions
Why did third-party online marketplace sales turn negative in Q3?
Direct website sales grew 13%, yet total e-commerce fell 4.2% to $18.2 million. Investors need to know whether Amazon sales dropped because of listing disruptions, lower ad efficiency, or customers switching to cheaper rival supplements.
How many clinics currently offer Niagen Plus infusions and injections?
The company stopped reporting its clinic footprint after reaching 1,200 locations in the first quarter, and pharmaceutical-grade sales stayed flat at $0.4 million in the third quarter despite the May launch of at-home injection kits.
Will lower ingredient demand force changes to the supplier contract?
Food-grade ingredient sales fell 46.9% to $3.4 million this quarter while inventories sat at $20.5 million. Management has not explained how it will handle its $20.5 million binding purchase commitment with W.R. Grace through June 2027.
What is the status of the Thorne patent challenge and Elysium appeal?
The earnings release gave no update on the Patent Trial and Appeal Board decision regarding Thorne's challenge to the '506 patent or the Federal Circuit ruling on the unaccrued $10.4 million Elysium legal fee award.